Independent study demonstrates novel AI-ECG algorithm could provide a cost-effective strategy for improving cardiac risk stratification Southlake, Texas, Nov. 10, 2022 — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences”…
We sit at the forefront of a brand new era for ECGs. Sound dramatic? That’s because it is. People think of the conventional ECG as something that will diagnose you…
Data generated by our AI-based technology has been peer reviewed in several prominent medical journals, including @JACC Journals and @ESC_Journals. What were some of the findings? https://twitter.com/i/status/1587149397388926976
Do you think home devices like the Apple Watch are going to eat into our potential market share? Think again. These devices are actually hugely beneficial. Our CEO Andrew Simpson…
Shared by Ken Dropiewski on October 25, 2022 Patent builds on previously granted U.S. patent as well as strengthens and diversifies the IP portfolio and further protects future revenues Southlake, Texas, Oct. 25,…
Patent builds on previously granted U.S. patent as well as strengthens and diversifies the IP portfolio and further protects future revenues Southlake, Texas, Oct. 25, 2022 — Heart Test Laboratories, Inc. d/b/a…
